These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
556 related articles for article (PubMed ID: 28987602)
1. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment. Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer. Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387 [TBL] [Abstract][Full Text] [Related]
3. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors. Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841 [TBL] [Abstract][Full Text] [Related]
4. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors. Duan Y; Yu T; Jin L; Zhang S; Shi X; Zhang Y; Zhou N; Xu Y; Lu W; Zhou H; Zhu H; Bai S; Hu K; Guan Y Eur J Med Chem; 2023 Jun; 254():115367. PubMed ID: 37086699 [TBL] [Abstract][Full Text] [Related]
5. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059 [TBL] [Abstract][Full Text] [Related]
6. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment. Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982 [TBL] [Abstract][Full Text] [Related]
9. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors. Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930 [TBL] [Abstract][Full Text] [Related]
11. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment. Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714 [TBL] [Abstract][Full Text] [Related]
12. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation. Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189 [TBL] [Abstract][Full Text] [Related]